Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,